Aurinia Pharmaceuticals Inc.
In the published model solve dated 2026-Q2, anchored at $16.08, Aurinia Pharmaceuticals Inc. (AUPH) is priced for +10.3% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• Essentially all revenue comes from one medicine, and the 10-K says so directly: the business is ⟦"substantially dependent on our ability to successfully commercialize LUPKYNIS, our sole approved product"⟧. • That single product converts unusually well, turning 41.7% of sales into operating profit on a trailing basis, which puts it alongside the most profitable specialty pharma names in its cohort rather than among the loss-makers. • Reported bottom-line profit for 2025 is flattered by an accou
Is AUPH overvalued? See what's priced in →
247 institutional managers reported holding AUPH in 13F filings for the quarter ended 2026-03-31. Together they hold about 54% of the company; the top 10 hold 30%. 33 opened new positions that quarter. Held by BlackRock, Two Sigma, Arrowstreet Capital, among others. On the short side, 9.3M shares were sold short as of the 2026-06-15 count, about 7% of shares outstanding (7.7 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
AUPH's share count grew 3.2% over the past five years even with $174.56M spent on repurchases. It pays no dividend. Cash returned over the past three years: $174.56M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at AUPH over the trailing three years: 2024: 3 buys totaling $10.82M; 2025: 9 buys totaling $26.30M; 2026: 7 buys totaling $25.14M. 12 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
AUPH's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-05 | -1.1% | -11.0% |
| 2023-08-04 | -3.1% | -25.7% |
| 2023-11-03 | +15.4% | +2.1% |
| 2024-05-03 | -1.9% | +10.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
AUPH's latest 8-K filings: 2026-08-19 (items 8.01); 2026-08-06 (items 2.02, 9.01); 2026-06-04 (items 5.07, 9.01); 2026-05-11 (items 2.01, 9.01); 2026-05-07 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.